R. Palakodeti

This study identifies Ertugliflozin as a potential treatment for COVID-19 through computational screening and experimental validation of its ability to inhibit RBD-ACE2 binding and modulate inflammatory responses.

This study evaluates four tyrosine kinase inhibitors for their anti-inflammatory and anti-thrombogenic effects against COVID-19 using in silico and 3D-human vascular lung models, suggesting they could be repurposed as targeted therapies.

This paper identifies Homoharringtonine as a potential repurposed drug for COVID-19 by demonstrating its ability to block RBD-ACE2 binding and show anti-inflammatory and anti-thrombogenic effects in a 3D human vascular lung model.